NCT07129850Not yet recruiting
Bempedoic Acid in PPCI Impact on Clinical Outcome and Inflammatory Markers
Bempedoic Acid in Primary Percutaneous Coronary Intervention: Impact on Inflammatory Markers, Procedural and Clinical Outcomes
Source: ClinicalTrials.gov · Last updated 19 Aug 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Bempedoic acid in PPCI
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 100 (estimated)
- First submitted
- 12 Aug 2025
- Start date
- 14 Aug 2025
- Primary completion date
- 14 Aug 2026
- Lead sponsor
- Assiut University
- Diseases
- Coronary artery disease
- NCT number
- NCT07129850
What you commit to
- Study type: Observational
- Planned participants: 100
- From 14 Aug 2025 to the primary completion date, 14 Aug 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Known allergy to Bempedoic acid Active infection or chronic inflammatory disease Severe hepatic or renal dysfunction Use of immunosuppressive therapy
Who the study is looking for
- Age ≥18 years STEMI diagnosis Undergoing primary PCI
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.